VIR CEO George Scangos was as crotchety as ever on today’s GS webcast. (Could he have been irked that Aduhelm was approved?) He claims that VIR’s adding IFN to its HBV cocktail was a brilliant insight that all other HBV companies will end up copying.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”